+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 99 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating molnupiravir, a study medicine designed to stop the COVID-19 virus from multiplying, to see if it can prevent severe illness from COVID-19 more effectively than a placebo in people who are at high risk. The focus is on non-hospitalized adults with COVID-19 who have certain health conditions or factors that increase their chance of severe illness, which can require hospitalization or lead to death. Participants will be randomly assigned to receive either 800 mg of molnupiravir orally every 12 hours for 5 days a total of 10 doses or a matching placebo on the same schedule. Some participants may also receive remdesivir as standard care if clinically appropriate. This is a phase 3, double-blind, placebo-controlled study comparing molnupiravir versus placebo. During the study, participants will be monitored for up to 29 days for outcomes such as hospitalization, death, and COVID-19-related medically attended visits. Researchers will assess adverse events and discontinuation due to side effects over approximately 5 months. Other measures include tracking symptom relief, changes in virus levels, and need for medical interventions. The total participation duration covers treatment and follow-up monitoring to evaluate safety and effectiveness.

Age: 18Years +All GendersPhase 3
227 locations
A

Actively Recruiting

Researchers are evaluating the safety and effectiveness of a device called RD2 Ver.02 compared to a control treatment for managing transsphincteric and long intersphincteric anal fistulas. The study aims to assess the complication rate within 6 months, recurrence rates at 12 months after treatment, and the incidence of perirectal infection by 6 months. This is a prospective, multi-center, double-blind, randomized controlled trial conducted by RedDress Ltd. Participants will be randomly assigned to one of two groups. Both groups will undergo debridement of the fistula tract, suturing of the internal opening, and a water leak test to ensure sealing. In the treatment group, the patients own coagulating blood RD2 Ver.02 will be applied inside the fistula tract to serve as a provisional matrix. In the control group, the blood sample will be discarded, and saline will be applied instead. Treatments are performed in the operating room. Participants will be monitored for healing and complications through 6 to 12 months post-treatment. The primary outcome is the combined healing rate of anal fistulas at 6 months. Secondary outcomes include clinical recurrence at 12 months and incidence of perirectal infections at 6 months. Blood samples, clinical evaluations, and imaging pelvic MRI are used to assess eligibility and monitor safety and efficacy. The trial will continue enrollment and follow-up until June 2028.

Age: 18Years +All GendersPhase Not Applicable
10 locations
C

Actively Recruiting

The COPE-AKI trial is a randomized study investigating a new process-of-care approach for patients hospitalized with acute kidney injury AKI. It aims to see if this multimodal intervention can increase the number of hospital-free days within 90 days after discharge compared to usual care. The study also looks at whether the intervention reduces serious kidney problems, repeated AKI episodes, and improves patient-reported health outcomes over the same period. Participants are randomly assigned to one of two groups the multimodal intervention or usual care. The intervention includes physician oversight with follow-up care recommendations at discharge, support from a nurse navigator for education and symptom monitoring, and pharmacist-led medication review and reconciliation. Those in the usual care group receive written kidney disease information and advice to follow up with a physician but do not receive additional study team support. Throughout the study, participants are monitored for hospital readmissions and kidney-related events up to 365 days after discharge. Patient-reported outcomes such as quality of life and social support are collected at multiple time points. The study involves regular follow-up visits by a research coordinator to collect data, with the primary focus on hospital-free days through 90 days and secondary outcomes measured through 180 and 365 days. The total participation lasts up to one year.

Age: 18Years +All GendersPhase Not Applicable
9 locations
S

Actively Recruiting

Researchers are studying LTI-03, an experimental inhaled medication, for the treatment of Idiopathic Pulmonary Fibrosis IPF, a progressive and fatal lung disease that causes scarring and loss of lung function. The study aims to assess the safety, side effects, and potential benefits of LTI-03 in improving lung scarring and symptoms in patients diagnosed with IPF within the last five years. Participants on stable doses of certain approved IPF medications may join. The study is a Phase 2, randomized, double-blind, placebo-controlled trial comparing LTI-03 to a placebo. Participants will inhale LTI-03 or placebo capsules twice daily using a dry powder inhaler. The trial includes a 28-day screening period, a 24-week treatment period, and a 4-week follow-up. Lung scans will be done at the start and end of treatment, with several clinic visits throughout the study. Participants will attend up to nine clinic visits where lung function tests, blood samples for safety and disease markers, and questionnaires about IPF symptoms will be conducted. Safety will be monitored through physical exams, vital signs, heart tests, and tracking side effects and medication changes. The main outcome will measure safety by recording treatment-related side effects over 24 weeks, while lung function and lung scarring changes will also be evaluated.

Age: 40Years +All GendersPhase 2
48 locations
P

Actively Recruiting

Researchers are evaluating the drug INCA033989 compared with the best available therapy in participants who have essential thrombocythemia ET with a CALR mutation and who have previously been treated with cytoreductive therapy. This phase 3, randomized, open-label study aims to assess the treatment effects in this specific group of patients with high-risk ET. Participants will receive either INCA033989 administered intravenously according to the study protocol or the best available therapy chosen by the investigator. The study treatments are given in parallel groups and will be monitored to compare responses and safety. The main study period includes treatment and observation up to at least 48 weeks, with follow-up for adverse events for 60 days after the last dose. During the study, participants will attend regular visits for assessments including clinical and hematologic responses, mutation frequency measurements, symptom assessments, and fatigue evaluations. Researchers will monitor treatment-emergent adverse events and measure durable responses at weeks 24 and 48. The total study duration extends until November 2030, with ongoing monitoring of patient health and responses throughout the treatment and follow-up periods.

Age: 18Years +All GendersPhase 3
193 locations
E

Actively Recruiting

Researchers are evaluating the effects of three different doses of AZD8965 compared to a placebo in adults aged 40 and older with Idiopathic Pulmonary Fibrosis IPF. This Phase IIb study aims to assess how well AZD8965 works, its safety, and how well participants tolerate it. Participants include those on stable doses of approved antifibrotic therapies and those not receiving such treatments. Participants will be randomly assigned to one of four groups placebo, low dose, medium dose, or high dose of AZD8965. The study lasts 24 weeks and is conducted globally at approximately 200 sites. This is a double-blind, placebo-controlled, parallel-group study, meaning neither participants nor researchers know which treatment any participant receives during the trial. During the study, participants will have their lung function measured by changes in forced vital capacity FVC at 24 weeks, along with monitoring for safety through the recording of adverse events. Additional assessments include examining the relationship between dose and efficacy, rate of lung function decline, and pharmacokinetics of AZD8965. The total participation time is 24 weeks with safety follow-up up to 25 weeks.

Age: 40Years +All GendersPhase 2
198 locations
E

Actively Recruiting

Researchers are evaluating the efficacy, safety, and tolerability of balcinrenone combined with dapagliflozin compared to dapagliflozin alone in adults with chronic kidney disease CKD Stage 3b and 4, who have an estimated glomerular filtration rate eGFR between 15 and less than 45 mLmin1.73 m2. This Phase III study focuses on a population with high unmet medical needs and increased risk of CKD progression, often excluded from other trials. The main goal is to see if the combination reduces cardiovascular death, kidney failure, and heart failure events. Participants will be randomly assigned to one of two groups one receiving a daily capsule containing balcinrenone 15 mg and dapagliflozin 10 mg plus a placebo tablet matching dapagliflozin, and the other receiving a dapagliflozin 10 mg tablet plus a placebo capsule matching balcinrenonedapagliflozin. All treatments are taken orally once daily alongside standard of care therapy. The study is conducted globally at approximately 550 sites in about 30 countries. During the study, participants will be monitored for up to 46 months to track outcomes such as cardiovascular death, kidney failure, and decline in kidney function measured by eGFR. Researchers will also assess changes in urinary albumin to creatinine ratio and overall safety and tolerability. Participants will have regular visits for assessments including laboratory tests and clinical evaluations to measure these outcomes and monitor health status throughout the study.

Age: 18Years - 99YearsAll GendersPhase 3
478 locations
R

Actively Recruiting

Researchers are evaluating the safety and effectiveness of the Multi-Pole Pulmonary Artery Radiofrequency Ablation Enhancor System for pulmonary artery denervation PADN in patients who have combined pre- and post-capillary pulmonary hypertension CpcPH linked to left heart disease LHD. This randomized controlled trial compares the investigational device to standard medical therapy in patients with chronic heart failure who are stable and receiving guideline-directed medical therapy GDMT. Participants will be divided into two groups one receiving PADN plus GDMT and the other receiving a placebo procedure plus GDMT. Before randomization, selected operators may enroll roll-in subjects to gain experience with the PADN procedure. Patients will undergo pulmonary artery angiography and radiofrequency ablation at specific sites in the pulmonary artery to deliver energy during PADN. Follow-up visits are scheduled at 1, 6, 12, 24, and 36 months, with an option for control patients meeting criteria to cross over to PADN at 24 months. Throughout the study, participants will have clinical assessments including heart failure event monitoring, cardiovascular hospitalizations, heart function tests such as NT-proBNP levels and 6-minute walk distance, and quality of life questionnaires. Safety will be evaluated within 30 days post-procedure, while efficacy endpoints will be reviewed after 12 months. The total study duration extends up to 3 years with regular follow-up visits to monitor health outcomes and device effects.

Age: 18Years - 85YearsAll GendersPhase Not Applicable
18 locations
E

Actively Recruiting

Researchers are studying the effects and safety of different doses of the investigational drug NNC0662-0419 in adults living with type 2 diabetes. This study compares NNC0662-0419 to semaglutide, an approved treatment for type 2 diabetes, and a placebo. The purpose is to find out if NNC0662-0419 is effective and safe for treating this condition. Participants will receive one of the three treatments NNC0662-0419, semaglutide, or placebo, all given as weekly injections under the skin. The dose of NNC0662-0419 will be gradually increased over time. The study uses a randomized design where the treatment assignment is by chance, and both participants and researchers do not know the group assignments. Throughout the study, participants will attend visits and undergo assessments at various weeks up to week 48. Researchers will measure blood sugar control using glycated hemoglobin HbA1c at weeks 16, 28, and 40, as well as body weight, blood glucose levels, cholesterol, kidney function, and other health markers. Safety will be monitored by recording any adverse events. The total study participation will last several months with regular monitoring.

Age: 18Years - 75YearsAll GendersPhase 2
63 locations
E

Actively Recruiting

Researchers are evaluating UBT251, a new medication, in adults with type 2 diabetes to determine its effectiveness and safety. The study compares UBT251 to a placebo and also includes a comparison to semaglutide, an existing treatment for type 2 diabetes. The trial is designed as a phase 2 study to find the appropriate dose and assess treatment impact on blood sugar control. Participants will be randomly assigned to one of four groups receiving UBT251, UBT251 placebo, semaglutide, or semaglutide placebo. Each participant will receive their assigned treatment once weekly by subcutaneous injection. The study includes a treatment period lasting up to 40 weeks, with evaluations at various points including weeks 16, 28, and 40. Throughout the study, participants will undergo regular assessments such as measuring glycated hemoglobin HbA1c to track blood sugar levels, body weight, insulin resistance, blood pressure, cholesterol, and kidney function. Safety will be monitored by recording treatment-emergent adverse events up to 46 weeks. The total participation time covers baseline, treatment, and follow-up visits to evaluate the study outcomes comprehensively.

Age: 18Years - 75YearsAll GendersPhase 2
70 locations

1-10 of 99

1